According to Jazz Pharmaceuticals's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.96165. At the end of 2023 the company had a P/S ratio of 2.02.
Year | P/S ratio | Change |
---|---|---|
2023 | 2.02 | -26.32% |
2022 | 2.74 | 8.31% |
2021 | 2.53 | -35.48% |
2020 | 3.92 | 1.18% |
2019 | 3.88 | 2.84% |
2018 | 3.77 | -24.41% |
2017 | 4.99 | 13.64% |
2016 | 4.39 | -32.53% |
2015 | 6.50 | -23.17% |
2014 | 8.47 | 0.87% |
2013 | 8.39 | 59.2% |
2012 | 5.27 | -11.86% |
2011 | 5.98 | 32.17% |
2010 | 4.53 | 136.01% |
2009 | 1.92 | 173.21% |
2008 | 0.7018 | -87.3% |
2007 | 5.53 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Novartis NVS | 3.88 | 97.59% | ๐จ๐ญ Switzerland |
AmerisourceBergen
ABC | 0.1421 | -92.76% | ๐บ๐ธ USA |
Endo International
ENDPQ | 0.0000 | -100.00% | ๐ฎ๐ช Ireland |
Teva Pharmaceutical Industries TEVA | 0.9982 | -49.12% | ๐ฎ๐ฑ Israel |